Key result
In 2016, numerous studies consolidated the validity of transcatheter approaches for valvular heart disease across various patient subsets, expanding the role of percutaneous interventions.
The 2016 year in review for valvular heart disease highlights the rapid expansion and validation of transcatheter therapies, particularly TAVI for intermediate-risk patients.
It is well known that ageing of the population is associated with a higher prevalence of VHD.
No takes yet. Share an insight, caveat, or question.
Alfieri et al. (2017) conducted a review in Valvular heart disease. Various percutaneous and surgical interventions was evaluated. In 2016, numerous studies consolidated the validity of transcatheter approaches for valvular heart disease across various patient subsets, expanding the role of percutaneous interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: